Development of high-throughput ATR-FTIR technology for rapid triage of brain cancer

Holly J. Butler, Paul M. Brennan, James M. Cameron, Duncan Finlayson, Mark G. Hegarty, Michael D. Jenkinson, David S. Palmer, Benjamin R. Smith, Matthew J. Baker

Research output: Contribution to journalArticle

Abstract

Non-specific symptoms, as well as the lack of a cost-effective test to triage patients in primary care, has resulted in increased time-to-diagnosis and a poor prognosis for brain cancer patients. A rapid, cost-effective, triage test could significantly improve this patient pathway. A blood test using attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy for the detection of brain cancer, alongside machine learning technology, is advancing towards clinical translation. However, whilst the methodology is simple and does not require extensive sample preparation, the throughput of such an approach is limited. Here we describe the development of instrumentation for the analysis of serum that is able to differentiate cancer and control patients at a sensitivity and specificity of 93.2% and 92.8%. Furthermore, preliminary data from the first prospective clinical validation study of its kind are presented, demonstrating how this innovative technology can triage patients and allow rapid access to imaging.

LanguageEnglish
Article number4501
Number of pages9
JournalNature Communications
Volume10
DOIs
Publication statusPublished - 8 Oct 2019

Fingerprint

Triage
Fourier Analysis
Brain Neoplasms
brain
Brain
Fourier transforms
cancer
Throughput
Infrared radiation
Technology
Learning systems
Costs
Blood
Imaging techniques
costs
Costs and Cost Analysis
machine learning
prognosis
Validation Studies
Hematologic Tests

Keywords

  • brain cancer
  • blood test
  • cost effective
  • ATR-FTIR technology
  • triage

Cite this

@article{b9ef1d02675d4677a6b0b7d589a60a54,
title = "Development of high-throughput ATR-FTIR technology for rapid triage of brain cancer",
abstract = "Non-specific symptoms, as well as the lack of a cost-effective test to triage patients in primary care, has resulted in increased time-to-diagnosis and a poor prognosis for brain cancer patients. A rapid, cost-effective, triage test could significantly improve this patient pathway. A blood test using attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy for the detection of brain cancer, alongside machine learning technology, is advancing towards clinical translation. However, whilst the methodology is simple and does not require extensive sample preparation, the throughput of such an approach is limited. Here we describe the development of instrumentation for the analysis of serum that is able to differentiate cancer and control patients at a sensitivity and specificity of 93.2{\%} and 92.8{\%}. Furthermore, preliminary data from the first prospective clinical validation study of its kind are presented, demonstrating how this innovative technology can triage patients and allow rapid access to imaging.",
keywords = "brain cancer, blood test, cost effective, ATR-FTIR technology, triage",
author = "Butler, {Holly J.} and Brennan, {Paul M.} and Cameron, {James M.} and Duncan Finlayson and Hegarty, {Mark G.} and Jenkinson, {Michael D.} and Palmer, {David S.} and Smith, {Benjamin R.} and Baker, {Matthew J.}",
year = "2019",
month = "10",
day = "8",
doi = "10.1038/s41467-019-12527-5",
language = "English",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",

}

Development of high-throughput ATR-FTIR technology for rapid triage of brain cancer. / Butler, Holly J.; Brennan, Paul M. ; Cameron, James M.; Finlayson, Duncan; Hegarty, Mark G.; Jenkinson, Michael D.; Palmer, David S.; Smith, Benjamin R.; Baker, Matthew J.

In: Nature Communications, Vol. 10, 4501 , 08.10.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of high-throughput ATR-FTIR technology for rapid triage of brain cancer

AU - Butler, Holly J.

AU - Brennan, Paul M.

AU - Cameron, James M.

AU - Finlayson, Duncan

AU - Hegarty, Mark G.

AU - Jenkinson, Michael D.

AU - Palmer, David S.

AU - Smith, Benjamin R.

AU - Baker, Matthew J.

PY - 2019/10/8

Y1 - 2019/10/8

N2 - Non-specific symptoms, as well as the lack of a cost-effective test to triage patients in primary care, has resulted in increased time-to-diagnosis and a poor prognosis for brain cancer patients. A rapid, cost-effective, triage test could significantly improve this patient pathway. A blood test using attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy for the detection of brain cancer, alongside machine learning technology, is advancing towards clinical translation. However, whilst the methodology is simple and does not require extensive sample preparation, the throughput of such an approach is limited. Here we describe the development of instrumentation for the analysis of serum that is able to differentiate cancer and control patients at a sensitivity and specificity of 93.2% and 92.8%. Furthermore, preliminary data from the first prospective clinical validation study of its kind are presented, demonstrating how this innovative technology can triage patients and allow rapid access to imaging.

AB - Non-specific symptoms, as well as the lack of a cost-effective test to triage patients in primary care, has resulted in increased time-to-diagnosis and a poor prognosis for brain cancer patients. A rapid, cost-effective, triage test could significantly improve this patient pathway. A blood test using attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy for the detection of brain cancer, alongside machine learning technology, is advancing towards clinical translation. However, whilst the methodology is simple and does not require extensive sample preparation, the throughput of such an approach is limited. Here we describe the development of instrumentation for the analysis of serum that is able to differentiate cancer and control patients at a sensitivity and specificity of 93.2% and 92.8%. Furthermore, preliminary data from the first prospective clinical validation study of its kind are presented, demonstrating how this innovative technology can triage patients and allow rapid access to imaging.

KW - brain cancer

KW - blood test

KW - cost effective

KW - ATR-FTIR technology

KW - triage

U2 - 10.1038/s41467-019-12527-5

DO - 10.1038/s41467-019-12527-5

M3 - Article

VL - 10

JO - Nature Communications

T2 - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 4501

ER -